Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot.

Rebolj M, Brentnall AR, Mathews C, Denton K, Holbrook M, Levine T, Sargent A, Smith J, Tidy J, Tyler X, Kitchener H; HPV Pilot Steering Group.

Br J Cancer. 2019 Aug 14. doi: 10.1038/s41416-019-0547-x. [Epub ahead of print]

PMID:
31409912
2.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group.

Lancet Oncol. 2019 Jul 22. pii: S1470-2045(19)30395-X. doi: 10.1016/S1470-2045(19)30395-X. [Epub ahead of print]

3.

Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: The psychological impact of primary screening (PIPS) study.

McBride E, Marlow LAV, Forster AS, Ridout D, Kitchener H, Patnick J, Waller J.

Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32540. [Epub ahead of print]

PMID:
31251820
4.

HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.

Gilham C, Sargent A, Kitchener HC, Peto J.

Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.

5.
6.

Optimising future cervical screening strategies.

Kitchener H.

Papillomavirus Res. 2019 Jun;7:201-203. doi: 10.1016/j.pvr.2019.04.001. Epub 2019 Apr 9.

7.

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Møller P, Möslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P, Snowsill TM, Steele R, Tischkowitz M; Manchester International Consensus Group, Evans DG.

Genet Med. 2019 Mar 28. doi: 10.1038/s41436-019-0489-y. [Epub ahead of print]

8.

Primary cervical screening with high risk human papillomavirus testing: observational study.

Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, Smith J, Evans C, Giles T, Frew V, Tyler X, Sargent A, Parker J, Holbrook M, Hunt K, Tidbury P, Levine T, Smith D, Patnick J, Stubbs R, Moss S, Kitchener H.

BMJ. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240.

9.

PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.

Kitson SJ, Maskell Z, Sivalingam VN, Allen JL, Ali S, Burns S, Gilmour K, Latheef R, Slade RJ, Pemberton PW, Shaw J, Ryder WD, Kitchener HC, Crosbie EJ.

Clin Cancer Res. 2019 Apr 15;25(8):2424-2432. doi: 10.1158/1078-0432.CCR-18-3339. Epub 2018 Dec 18.

10.

The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.

MacKintosh ML, Derbyshire AE, McVey RJ, Bolton J, Nickkho-Amiry M, Higgins CL, Kamieniorz M, Pemberton PW, Kirmani BH, Ahmed B, Syed AA, Ammori BJ, Renehan AG, Kitchener HC, Crosbie EJ.

Int J Cancer. 2019 Feb 1;144(3):641-650. doi: 10.1002/ijc.31913. Epub 2018 Nov 20.

11.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
12.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

13.

To promote maintenance or treatment, is that the question?

Bookman MA, Kitchener HC.

Lancet Oncol. 2017 Sep;18(9):1151-1152. doi: 10.1016/S1470-2045(17)30567-3. Epub 2017 Jul 25. No abstract available.

PMID:
28754484
14.

Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).

Tsiachristas A, Gittins M, Kitchener H, Gray A.

J Med Screen. 2018 Jun;25(2):99-109. doi: 10.1177/0969141317704679. Epub 2017 May 22.

15.

A cluster randomized trial of strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC trial.

Kitchener H, Gittins M, Cruickshank M, Moseley C, Fletcher S, Albrow R, Gray A, Brabin L, Torgerson D, Crosbie EJ, Sargent A, Roberts C.

J Med Screen. 2018 Jun;25(2):88-98. doi: 10.1177/0969141317696518. Epub 2017 May 22.

16.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
17.

Cervical cancer: A global health crisis.

Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK.

Cancer. 2017 Jul 1;123(13):2404-2412. doi: 10.1002/cncr.30667. Epub 2017 May 2. Review.

18.

The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.

Stuart GCE, Kitchener HC, Vermorken JB, Quinn MJ, Small W, Pujade-Lauraine E, Chou H, Wong M, Bacon M.

Int J Gynecol Cancer. 2017 May;27(4):813-818. doi: 10.1097/IGC.0000000000000934.

PMID:
30814180
19.

The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.

Stuart GCE, Kitchener HC, Vermorken JB, Quinn MJ, Small W Jr, Pujade-Lauraine E, Chou H, Wong M, Bacon M.

Int J Gynecol Cancer. 2017 May;27(4):813-818. doi: 10.1097/IGC.0000000000000934.

PMID:
28441253
20.

Is extending screening intervals safe in human papillomavirus-negative women?

Kitchener HC.

BJOG. 2017 Sep;124(10):1594. doi: 10.1111/1471-0528.14627. Epub 2017 May 2. No abstract available.

21.

Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen.

Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC, Townsend PA.

Cancer Med. 2017 Feb;6(2):408-415. doi: 10.1002/cam4.967. Epub 2017 Jan 21.

22.

Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme.

McBride E, Marlow L, Forster AS, Moss S, Myles J, Kitchener H, Patnick J, Waller J.

BMJ Open. 2016 Dec 23;6(12):e014356. doi: 10.1136/bmjopen-2016-014356.

23.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, Renehan AG, Kitchener HC, Edmondson RJ, Crosbie EJ.

Mod Pathol. 2017 Mar;30(3):459-468. doi: 10.1038/modpathol.2016.203. Epub 2016 Dec 2.

24.

Cervix Cancer Research Network (CCRN): Improving Access to Cervix Cancer Trials on a Global Scale.

Gaffney D, Small B, Kitchener H, Young Ryu S, Viswanathan A, Trimble T, Covens A, Wilailak S, Lertkhachonsuk AA, Sitathanee C, Mahantshetty U, Fisher B, Springer S, Pollatz T, Spiller A, Bacon M, Jhingran A.

Int J Gynecol Cancer. 2016 Nov;26(9):1690-1693. doi: 10.1097/IGC.0000000000000823.

PMID:
30814204
25.

Cervix Cancer Research Network (CCRN): Improving Access to Cervix Cancer Trials on a Global Scale.

Gaffney D, Small B, Kitchener H, Young Ryu S, Viswanathan A, Trimble T, Covens A, Wilailak S, Lertkhachonsuk AA, Sitathanee C, Mahantshetty U, Fisher B, Springer S, Pollatz T, Spiller A, Bacon M, Jhingran A.

Int J Gynecol Cancer. 2016 Nov;26(9):1690-1693.

PMID:
27779548
26.

Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.

Wan YL, Beverley-Stevenson R, Carlisle D, Clarke S, Edmondson RJ, Glover S, Holland J, Hughes C, Kitchener HC, Kitson S, Miles T, Morley R, Morrison J, Nelson L, Powell M, Sadler L, Tomlinson A, Tylko-Hill K, Whitcombe J, Crosbie EJ.

Gynecol Oncol. 2016 Nov;143(2):287-293. doi: 10.1016/j.ygyno.2016.08.333. Epub 2016 Sep 1.

27.

A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC).

Kitchener HC, Gittins M, Rivero-Arias O, Tsiachristas A, Cruickshank M, Gray A, Brabin L, Torgerson D, Crosbie EJ, Sargent A, Roberts C.

Health Technol Assess. 2016 Sep;20(68):1-138. doi: 10.3310/hta20680.

28.

Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.

Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K.

Int J Cancer. 2016 Dec 15;139(12):2771-2780. doi: 10.1002/ijc.30392.

29.

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):760-765. doi: 10.1016/j.clon.2016.06.011. Epub 2016 Jul 9.

30.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

31.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group.

Lancet Infect Dis. 2016 Oct;16(10):1154-1168. doi: 10.1016/S1473-3099(16)30120-7. Epub 2016 Jun 28.

PMID:
27373900
32.

A prospective study of anal cancer screening in HIV-positive and negative MSM.

Schofield AM, Sadler L, Nelson L, Gittins M, Desai M, Sargent A, McMahon RF, Hill J, Crosbie EJ, Patnick J, Kitchener HC.

AIDS. 2016 Jun 1;30(9):1375-83. doi: 10.1097/QAD.0000000000001045.

PMID:
26836788
33.

Measuring the biological effect of presurgical metformin treatment in endometrial cancer.

Sivalingam VN, Kitson S, McVey R, Roberts C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC, Crosbie EJ.

Br J Cancer. 2016 Feb 2;114(3):281-9. doi: 10.1038/bjc.2015.453. Epub 2016 Jan 21.

34.

Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium.

Sasieni P, Castanon A, Landy R, Kyrgiou M, Kitchener H, Quigley M, Poon L, Shennan A, Hollingworth A, Soutter WP, Freeman-Wang T, Peebles D, Prendiville W, Patnick J.

BJOG. 2016 Aug;123(9):1426-9. doi: 10.1111/1471-0528.13839. Epub 2015 Dec 23. No abstract available.

35.

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC.

Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. Review.

36.

Premalignant disease in the genital tract in pregnancy.

Owens GL, Kitchener HC.

Best Pract Res Clin Obstet Gynaecol. 2016 May;33:33-43. doi: 10.1016/j.bpobgyn.2015.10.009. Epub 2015 Oct 19.

PMID:
26597347
37.

Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.

Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum NR, Lecuru F, Small W Jr; Gynecologic Cancer InterGroup Cervix Cancer brainstorming day.

Int J Gynecol Cancer. 2016 Jan;26(1):199-207. doi: 10.1097/IGC.0000000000000587.

38.

HPV testing alone is not as safe as cytology and selective HPV testing: AGAINST: There is powerful evidence for primary cervical screening.

Kitchener H.

BJOG. 2016 Jan;123(1):68. doi: 10.1111/1471-0528.13638. Epub 2015 Nov 3. No abstract available.

39.

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM.

J Clin Oncol. 2015 Dec 10;33(35):4138-44. doi: 10.1200/JCO.2015.60.9719. Epub 2015 Sep 28.

PMID:
26417001
40.

The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.

Crosbie EJ, Bailey A, Sargent A, Gilham C, Peto J, Kitchener HC.

J Clin Microbiol. 2015 Nov;53(11):3553-9. doi: 10.1128/JCM.01578-15. Epub 2015 Sep 2.

41.

A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.

Sivalingam V, McVey R, Gilmour K, Ali S, Roberts C, Renehan A, Kitchener H, Crosbie E.

Lancet. 2015 Feb 26;385 Suppl 1:S90. doi: 10.1016/S0140-6736(15)60405-6.

PMID:
26312913
42.

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters.

Versluis MA, de Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, de Bock GH, Nijman HW.

Br J Cancer. 2015 Sep 1;113(5):786-93. doi: 10.1038/bjc.2015.268. Epub 2015 Jul 28.

43.

Holistic assessment of women with hyperemesis gravidarum: A randomised controlled trial.

Fletcher SJ, Waterman H, Nelson L, Carter LA, Dwyer L, Roberts C, Torgerson D, Kitchener H.

Int J Nurs Stud. 2015 Nov;52(11):1669-77. doi: 10.1016/j.ijnurstu.2015.06.007. Epub 2015 Jun 25.

PMID:
26212603
44.

The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.

Gaffney DK, Suneja G, Ryu SY, McCormick M, Plante M, Mileshkin L, Small W Jr, Bacon M, Stuart G, Kitchener H.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):506-8. doi: 10.1016/j.ijrobp.2015.02.054. No abstract available.

45.

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM.

Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.

PMID:
26002111
46.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

47.

A study of cellular counting to determine minimum thresholds for adequacy for liquid-based cervical cytology using a survey and counting protocol.

Kitchener HC, Gittins M, Desai M, Smith JH, Cook G, Roberts C, Turnbull L.

Health Technol Assess. 2015 Mar;19(22):i-xix, 1-64. doi: 10.3310/hta19220.

48.

The cervix cancer research network: increasing access to cancer clinical trials in low- and middle-income countries.

Suneja G, Bacon M, Small W Jr, Ryu SY, Kitchener HC, Gaffney DK.

Front Oncol. 2015 Feb 19;5:14. doi: 10.3389/fonc.2015.00014. eCollection 2015.

49.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL.

Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.

50.

HPV primary cervical screening: time for a change.

Kitchener HC.

Cytopathology. 2015 Feb;26(1):4-6. doi: 10.1111/cyt.12236. No abstract available.

PMID:
25683358

Supplemental Content

Loading ...
Support Center